#BEGIN_DRUGCARD DB00239

# AHFS_Codes:
Not Available

# ATC_Codes:
D01AC11
G01AF17

# Absorption:
Systemic absorption of oxiconazole is low.

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Oxistat

# CAS_Registry_Number:
64211-46-7

# ChEBI_ID:
Not Available

# Chemical_Formula:
C18H13Cl4N3O

# Chemical_IUPAC_Name:
(E)-[1-(2,4-dichlorophenyl)-2-(1H-imidazol-1-yl)ethylidene][(2,4-dichlorophenyl)methoxy]amine

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
2230452

# Description:
Oxiconazole nitrate (U.S.: Oxistat, Canada: Oxizole) is an antifungal medication typically administered in a cream or lotion to treat skin infections such as athlete's foot, jock itch and ringworm. [Wikipedia]

# Dosage_Forms:
Cream	Topical
Lotion	Topical

# Drug_Category:
Antifungal Agents

# Drug_Interactions:
Not Available

# Drug_Reference:
18468760	Matsui H, Sakanashi Y, Oyama TM, Oyama Y, Yokota S, Ishida S, Okano Y, Oyama TB, Nishimura Y: Imidazole antifungals, but not triazole antifungals, increase membrane Zn2+ permeability in rat thymocytes Possible contribution to their cytotoxicity. Toxicology. 2008 Jun 27;248(2-3):142-50. Epub 2008 Apr 7.
3069196	Fromtling RA: Overview of medically important antifungal azole derivatives. Clin Microbiol Rev. 1988 Apr;1(2):187-217.

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Oxiconazole

# HET_ID:
Not Available

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C18H13Cl4N3O/c19-13-2-1-12(16(21)7-13)10-26-24-18(9-25-6-5-23-11-25)15-4-3-14(20)8-17(15)22/h1-8,11H,9-10H2/b24-18-

# InChI_Key:
InChIKey=QRJJEGAJXVEBNE-MOHJPFBDSA-N

# Indication:
For treatment of dermal fungal infection.

# KEGG_Compound_ID:
C08075

# KEGG_Drug_ID:
D00885

# LIMS_Drug_ID:
239

# Mechanism_Of_Action:
Oxiconazole inhibits ergosterol biosynthesis, which is required for cytoplasmic membrane integrity of fungi. It acts to destabilize the fungal cyctochrome P450 51 enzyme (also known as Lanosterol 14-alpha demethylase). This is vital in the cell membrance structure of the fungus. Its inhibition leads to cell lysis. Oxiconazole has also been shown in inhibit DNA synthesis and suppress intracellular concentrations of ATP. Like other imidazole antifungals, Oxiconazole can increase membrane permeability to zinc, augmenting its cytotoxicity.

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
429.127

# Molecular_Weight_Mono:
426.981272881

# Organisms_Affected:
Fungi

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/oxi1314.shtml

# Pathways:
Not Available

# PharmGKB_ID:
PA164754742

# Pharmacology:
Oxiconazole is a broad-spectrum imidazole derivative whose antifungal activity is derived primarily from the inhibition of ergosterol biosynthesis, which is critical for cellular membrane integrity. It has fungicidal or fungistatic activity in vitro against a number of pathogenic fungi including the following dermatophytes, and yeasts: <i>T. rubrum</i>, <i>T. mentagrophytes</i>, <i>T. tonsurans</i>, <i>T. violaceum</i>, <i>E. floccosum</i>, <i>M. canis</i>, <i>M. audouini</i>, <i>M. gypseum</i>, <i>C. albicans</i>, and <i>M. furfur</i>.

# Predicted_LogP_Hydrophobicity:
5.28

# Predicted_LogS:
-5.3

# Predicted_Water_Solubility:
1.91e-03 g/l

# Primary_Accession_No:
DB00239

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
5361463

# PubChem_Substance_ID:
46504752

# RxList_Link:
http://www.rxlist.com/cgi/generic3/oxico.htm

# Salts:
Not Available

# Secondary_Accession_No:
APRD01154

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
ClC1=CC(Cl)=C(CO\N=C(\CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Oxiconazol [INN-Spanish]
Oxiconazole Nitrate
Oxiconazolum [INN-Latin]

# Synthesis_Reference:
Not Available

# Toxicity:
Side effects incliude pruritus, burning, irritation, erythema, stinging and allergic contact dermatitis and folliculitis, fissuring, maceration rash and nodules.

# Update_Date:
2013-02-08 16:19:12 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Oxiconazole

# pKa_Isoelectric_Point:
Not Available

# Phase_1_Metabolizing_Enzyme_1_Gene_Name:
CYP3A4

# Phase_1_Metabolizing_Enzyme_1_ID:
4512

# Phase_1_Metabolizing_Enzyme_1_Name:
Cytochrome P450 3A4

# Phase_1_Metabolizing_Enzyme_1_Protein_Sequence:
>Cytochrome P450 3A4
MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNILSYHKGFCMF
DMECHKKYGKVWGFYDGQQPVLAITDPDMIKTVLVKECYSVFTNRRPFGPVGFMKSAISI
AEDEEWKRLRSLLSPTFTSGKLKEMVPIIAQYGDVLVRNLRREAETGKPVTLKDVFGAYS
MDVITSTSFGVNIDSLNNPQDPFVENTKKLLRFDFLDPFFLSITVFPFLIPILEVLNICV
FPREVTNFLRKSVKRMKESRLEDTQKHRVDFLQLMIDSQNSKETESHKALSDLELVAQSI
IFIFAGYETTSSVLSFIMYELATHPDVQQKLQEEIDAVLPNKAPPTYDTVLQMEYLDMVV
NETLRLFPIAMRLERVCKKDVEINGMFIPKGVVVMIPSYALHRDPKYWTEPEKFLPERFS
KKNKDNIDPYIYTPFGSGPRNCIGMRFALMNMKLALIRVLQNFSFKPCKETQIPLKLSLG
GLLQPEKPVVLKVESRDGTVSGA

# Phase_1_Metabolizing_Enzyme_1_SwissProt_ID:
P08684

# Phase_1_Metabolizing_Enzyme_2_Gene_Name:
CYP2C19

# Phase_1_Metabolizing_Enzyme_2_ID:
6016

# Phase_1_Metabolizing_Enzyme_2_Name:
Cytochrome P450 2C19

# Phase_1_Metabolizing_Enzyme_2_Protein_Sequence:
>Cytochrome P450 2C19
MDPFVVLVLCLSCLLLLSIWRQSSGRGKLPPGPTPLPVIGNILQIDIKDVSKSLTNLSKI
YGPVFTLYFGLERMVVLHGYEVVKEALIDLGEEFSGRGHFPLAERANRGFGIVFSNGKRW
KEIRRFSLMTLRNFGMGKRSIEDRVQEEARCLVEELRKTKASPCDPTFILGCAPCNVICS
IIFQKRFDYKDQQFLNLMEKLNENIRIVSTPWIQICNNFPTIIDYFPGTHNKLLKNLAFM
ESDILEKVKEHQESMDINNPRDFIDCFLIKMEKEKQNQQSEFTIENLVITAADLLGAGTE
TTSTTLRYALLLLLKHPEVTAKVQEEIERVVGRNRSPCMQDRGHMPYTDAVVHEVQRYID
LIPTSLPHAVTCDVKFRNYLIPKGTTILTSLTSVLHDNKEFPNPEMFDPRHFLDEGGNFK
KSNYFMPFSAGKRICVGEGLARMELFLFLTFILQNFNLKSLIDPKDLDTTPVVNGFASVP
PFYQLCFIPV

# Phase_1_Metabolizing_Enzyme_2_SwissProt_ID:
P33261

# Drug_Target_1_Cellular_Location:
Not Available

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
12383016	Rossello A, Bertini S, Lapucci A, Macchia M, Martinelli A, Rapposelli S, Herreros E, Macchia B: Synthesis, antifungal activity, and molecular modeling studies of new inverted oxime ethers of oxiconazole. J Med Chem. 2002 Oct 24;45(22):4903-12.
16964330	Carrillo-Munoz AJ, Giusiano G, Ezkurra PA, Quindos G: Antifungal agents: mode of action in yeast cells. Rev Esp Quimioter. 2006 Jun;19(2):130-9.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
X13296

# Drug_Target_1_GenBank_ID_Protein:
578119

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
ERG11

# Drug_Target_1_Gene_Sequence:
>1587 bp
ATGGCTATTGTTGAAACTGTCATTGATGGCATTAATTATTTTTTGTCCCTTAGTGTTACA
CAACAGATCAGTATATTATTAGGGGTTCCATTTGTTTACAACTTAGTATGGCAATATTTA
TATTCATTAAGAAAAGATAGAGCTCCATTAGTGTTTTATTGGATTCCTTGGTTTGGTTCT
GCAGCTTCATATGGTCAACAACCTTATGAATTTTTCGAATCATGTCGTCAAAAGTATGGT
GATGTATTTTCATTTATGTTATTAGGGAAAATTATGACGGTTTATTTAGGTCCAAAAGGT
CATGAATTTGTTTTTAATGCTAAATTATCTGATGTTTCTGCTGAAGATGCTTATAAACAT
TTAACTACTCCAGTTTTCGGTAAAGGGGTTATTTATGATTGTCCAAATTCCAGATTAATG
GAACAAAAAAAATTTGCTAAATTTGCTTTGACTACTGATTCATTTAAAAGATATGTTCCT
AAGATTAGAGAAGAAATTTTGAATTATTTTGTTACTGATGAAAGTTTCAAATTGAAAGAA
AAAACTCATGGGGTTGCCAATGTTATGAAAACTCAACCAGAAATTACTATTTTCACTGCT
TCAAGATCTTTATTTGGTGATGAAATGAGAAGAATTTTTGACCGTTCATTTGCTCAACTA
TATTCTGATTTAGATAAAGGTTTTACCCCTATTAATTTTGTTTTCCCTAATTTACCTTTA
CCTCATTATTGGAGACGTGATGCTGCTCAAAAGAAAATCTCTGCTACTTATATGAAAGAA
ATTAAACTGAGAAGAGAACGTGGTGATATTGATCCAAATCGTGATTTAATTGATTCCTTA
TTGATTCATTCAACTTATAAAGATGGTGTGAAAATGACTGATCAAGAAATTGCTAATCTT
TTAATTGGTATTCTTATGGGTGGTCAACATACTTCTGCTTCTACTTCTGCTTGGTTCTTG
TTACATTTAGGTGAAAAACCTCATTTACAAGATGTTATTTATCAAGAAGTTGTTGAATTA
TTGAAAGAAAAAGGTGGTGATTTGAATGATTTGACTTATGAAGATTTACAAAAATTACCA
TCAGTCAATAACACTATTAAGGAAACTCTCAGAATGCATATGCCATTACATTCTATTTTT
AGAAAAGTTACTAACCCATTAAGAATCCCTGAAACCAATTATATTGTTCCAAAAGGTCAT
TATGTTTTAGTTTCTCCAGGTTATGCTCATACTAGTGAAAGATATTTTGATAACCCTGAA
GATTTTGATCCAACTAGATGGGATACTGCTGCTGCCAAAGCTAATTCTGTTTCATTTAAC
TCTTCTGATGAAGTTGATTATGGGTTTGGGAAAGTTTCTAAAGGGGTTTCTTCACCTTAT
TTACCATTTGGTGGTGGTAGACATAGATGTATTGGGGAACAATTTGCTTATGTTCAATTA
GGAACCATTTTAACTACTTTTGTTTATAATTTAAGATGGACTATTGATGGTTATAAAGTG
CCTGACCCTGATTATAGTTCAATGGTGGTTTTACCTACTGAACCAGCAGAAATCATTTGG
GAAAAAAGAGAAACTTGTATGTTTTAA

# Drug_Target_1_General_Function:
Secondary metabolites biosynthesis, transport and catabolism

# Drug_Target_1_General_References:
2644625	Lai MH, Kirsch DR: Nucleotide sequence of cytochrome P450 L1A1 (lanosterol 14 alpha-demethylase) from Candida albicans. Nucleic Acids Res. 1989 Jan 25;17(2):804.
7819160	Boscott PE, Grant GH: Modeling cytochrome P450 14 alpha demethylase (Candida albicans) from P450cam. J Mol Graph. 1994 Sep;12(3):185-92, 195.
9210671	White TC: The presence of an R467K amino acid substitution and loss of allelic variation correlate with an azole-resistant lanosterol 14alpha demethylase in Candida albicans. Antimicrob Agents Chemother. 1997 Jul;41(7):1488-94.
9228762	Loffler J, Kelly SL, Hebart H, Schumacher U, Lass-Florl C, Einsele H: Molecular analysis of cyp51 from fluconazole-resistant Candida albicans strains. FEMS Microbiol Lett. 1997 Jun 15;151(2):263-8.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
260

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
60676

# Drug_Target_1_Name:
Cytochrome P450 51

# Drug_Target_1_Number_of_Residues:
528

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00067	p450

# Drug_Target_1_Protein_Sequence:
>Cytochrome P450 51
MAIVETVIDGINYFLSLSVTQQISILLGVPFVYNLVWQYLYSLRKDRAPLVFYWIPWFGS
AASYGQQPYEFFESCRQKYGDVFSFMLLGKIMTVYLGPKGHEFVFNAKLSDVSAEDAYKH
LTTPVFGKGVIYDCPNSRLMEQKKFAKFALTTDSFKRYVPKIREEILNYFVTDESFKLKE
KTHGVANVMKTQPEITIFTASRSLFGDEMRRIFDRSFAQLYSDLDKGFTPINFVFPNLPL
PHYWRRDAAQKKISATYMKEIKSRRERGDIDPNRDLIDSLLIHSTYKDGVKMTDQEIANL
LIGILMGGQHTSASTSAWFLLHLGEKPHLQDVIYQEVVELLKEKGGDLNDLTYEDLQKLP
SVNNTIKETLRMHMPLHSIFRKVTNPLRIPETNYIVPKGHYVLVSPGYAHTSERYFDNPE
DFDPTRWDTAAAKANSVSFNSSDEVDYGFGKVSKGVSSPYLPFGGGRHRCIGEQFAYVQL
GTILTTFVYNLRWTIDGYKVPDPDYSSMVVLPTEPAEIIWEKRETCMF

# Drug_Target_1_Reaction:
obtusifoliol + 3 O2 + 3 NADPH + 3 H+ = 4alpha-methyl-5alpha-ergosta-8,14,24(28)-trien-3beta-ol + formate + 3 NADP+ + 4 H2O

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Catalyzes C14-demethylation of lanosterol which is critical for ergosterol biosynthesis. It transforms lanosterol into 4,4'-dimethyl cholesta-8,14,24-triene-3-beta-ol

# Drug_Target_1_SwissProt_ID:
P10613

# Drug_Target_1_SwissProt_Name:
CP51_CANAL

# Drug_Target_1_Synonyms:
CYPLI
EC 1.14.13.70
Lanosterol 14-alpha demethylase
P450-14DM
P450-LIA1
Sterol 14- alpha demethylase

# Drug_Target_1_Theoretical_pI:
7.19

# Drug_Target_1_Transmembrane_Regions:
15-37; 50-69

# Drug_Target_2_Cellular_Location:
Not Available

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
8144423	Gebre-Hiwot A, Frommel D: The in-vitro anti-leishmanial activity of inhibitors of ergosterol biosynthesis. J Antimicrob Chemother. 1993 Dec;32(6):837-42.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
Not Available

# Drug_Target_2_GenBank_ID_Gene:
Not Available

# Drug_Target_2_GenBank_ID_Protein:
Not Available

# Drug_Target_2_GeneCard_ID:
Not Available

# Drug_Target_2_Gene_Name:
ERG7

# Drug_Target_2_Gene_Sequence:
Not Available

# Drug_Target_2_General_Function:
Not Available

# Drug_Target_2_General_References:
Not Available

# Drug_Target_2_HGNC_ID:
Not Available

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
7194

# Drug_Target_2_Locus:
Not Available

# Drug_Target_2_Molecular_Weight:
Not Available

# Drug_Target_2_Name:
Lanosterol synthase

# Drug_Target_2_Number_of_Residues:
0

# Drug_Target_2_PDB_ID:
Not Available

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
Not Available

# Drug_Target_2_Protein_Sequence:
Not Available

# Drug_Target_2_Reaction:
Not Available

# Drug_Target_2_Signals:
Not Available

# Drug_Target_2_Specific_Function:
Not Available

# Drug_Target_2_SwissProt_ID:
Q04782

# Drug_Target_2_SwissProt_Name:
ERG7_CANAL

# Drug_Target_2_Synonyms:
Not Available

# Drug_Target_2_Theoretical_pI:
Not Available

# Drug_Target_2_Transmembrane_Regions:
Not Available

#END_DRUGCARD DB00239
